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Cancer risk management strategies and perceptions
of unaffected women 5 years after predictive genetic
testing for BRCA1/2 mutations
Claire Julian-Reynier*,1,2, Julien Mancini1,2,3, Emmanuelle Mouret-Fourme4,5, Marion Gauthier-Villars5,
Vale ´rie Bonadona6, Pascaline Berthet7, Jean-Pierre Fricker8, Olivier Caron9, Elisabeth Luporsi10 and
Catherine Nogue `s4,5
In a French national cohort of unaffected females carriers/non-carriers of a BRCA1/2 mutation, long-term preventive strategies
and breast/ovarian cancer risk perceptions were followed up to 5 years after test result disclosure, using self-administered
questionnaires. Response rate was 74%. Carriers (N¼101) were younger (average age±SD¼37±10) than non-carriers
(N¼145; 42±12). There were four management strategies that comprised 88% of the decisions made by the unaffected
carriers: 50% opted for breast surveillance alone, based on either magnetic resonance imaging (MRI) and other imaging (31%)
or mammography alone (19%); 38% opted for either risk reducing salpingo-oophorectomy (RRSO) and breast surveillance,
based on MRI and other imaging (28%) or mammography alone (10%). The other three strategies were: risk reducing
mastectomy (RRM) and RRSO (5%), RRM alone (2%) and neither RRM/RRSO nor surveillance (6%). The results obtained for
various age groups are presented here. Non-carriers often opted for screening despite their low cancer risk. Result disclosure
increased carriers’ short-term high breast/ovarian cancer risk perceptions (Pp0.02) and decreased non-carriers’ short- and
long-term perceptions (Po0.001). During follow-up, high breast cancer risk perceptions increased with time among those who
had no RRM and decreased in the opposite case; high ovarian cancer risk perceptions increased further with time among
those who had no RRSO and decreased in the opposite case; RRSO did not affect breast cancer risk perceptions. Informed
decision-making involves letting women know whether opting for RRSO and breast MRI surveillance is as effective in terms
of survival as RRM and RRSO.
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INTRODUCTION
Many surveys have addressed the short-term impact of BRCA1/2
genetic mutation testing on perceived risks and behavioural outcomes
in heterogeneous samples.1,2 In three prospective studies, unaffected
women were followed for 2 years3,4 and 3 years5 after disclosure of
their test results in a routine context, and only one study has followed
a selected sample of 23 women (21 of whom underwent risk reducing
mastectomy (RRM)) up to 5 years.6 The largest samples of unaffected
BRCA1/2 carriers studied so far included 53 (Foster et al5)a n d6 8
women.3 In these studies, the behaviour of cohorts of female non-
carriers from BRCA1/2 families was followed simultaneously. Another
study was speciﬁcally designed to describe the behaviour of this
group.7 A large Canadian survey retrospectively selected a large
number of unaffected BRCA1/2 carriers (N¼342) and followed their
preventive behaviours until 4 years after their test results on average.8
A decrease in breast and ovarian cancer risk perception has been
described in non-carriers 12 months after genetic testing, and a lower
breast cancer risk perception in non-carriers compared with carriers.
Only one study has shown that carriers’ risk perceptions were higher
6 months after disclosure than before testing.9 It has been concluded
that risk perception decreases with time.2
Behavioural outcomes have been described as rates of surveillance
or prophylactic surgery undergone by carriers/non-carriers: RRM is
undergone by most carriers in the Netherlands (55%) (Meijers-
Heijboer et al3) and Denmark,10 in a third of the UK series studied
(34%) (Foster et al5) and less frequently elsewhere.4,8,11 Although the
rates of risk reducing salpingo-oophorectomy (RRSO) reported were
higher, most of these studies made no reference to the age at which
the intervention should be proposed according to current guidelines.
Rates of compliance with mammographic surveillance have been
studied in women who were screened for 2 years after test disclosure,
but no information is available about the number of investigations
carried out. Women’s decision-making processes have been described
individually but no information has been published so far about the
follow-up of various age groups or about the whole series of decisions
on which their medical management depends. In particular, the
uptake of magnetic resonance imaging (MRI) by these cohorts as a
means of surveillance has not yet been documented.
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www.nature.com/ejhgThe aim of this study was ﬁrst to describe the sequences of
preventive decisions made by women up to 5 years after disclosure
of their test results and the surveillance/surgical options chosen by
various age groups. It was also proposed to examine the impact of
BRCA1/2 genetic testing and preventive strategies on these women’s
cancer risk perceptions with time. Women included in this prospective
national study were unaffected carriers/non-carriers who underwent a
baseline assessment before test result disclosure and regular follow-up
for the next 5 years. BRCA1/2 carriers’ and non-carriers’ long-term
risk perceptions were expected to depend not only on their carrier/
non-carrier status but also on the series of preventive strategies
chosen.
MATERIALS AND METHODS
Population
In the framework of the ongoing French ‘Genepso’ project managed by the
French Cancer Genetic Network, BRCA1/2 carriers attending 29 participating
centres were registered between 2000 and 2006. Only epidemiological data have
been published so far on this cohort, although other studies are under way.12–14
In this study on ‘Psychosocial and Preventive Behaviour’, non-carriers from
families where these BRCA1/2 mutations had been identiﬁed were included
along with carriers.
The behavioural characteristics of unaffected female carriers and non-
carriers of the deleterious BRCA1/2 mutation were therefore compared.
For this purpose, all the cases who reached the 5-year follow-up endpoint
were selected. In France, the cost of cancer genetic consultations, BRCA1/2
testing and any subsequent medical management of people at risk is covered by
the national healthcare system.
Questionnaires
Process. Consultees were asked to complete six self-administered question-
naires. The ﬁrst questionnaire, which was designed to collect baseline informa-
tion, was completed before disclosure of the BRCA1/2 genetic test results by all
the women. The women who agreed to participate to the follow-up were then
given a second questionnaire at disclosure, to be returned 15 days later. The
four other questionnaires were mailed to the women’s homes 6 months, 1 year,
2 years and 5 years later. If no answer had been received 1 month after
mailing a questionnaire, a reminder letter and a copy of the questionnaire were
sent out. All the questionnaires were mailed back to the coordinating centre.
The procedure used was approved by the ‘Comite ´ National Informatique
et Liberte ´s’.
The cancer geneticists also completed a questionnaire describing the
women’s family and medical characteristics at inclusion and follow-up.
Variables
Preventive behaviour. At the 5-year follow-up, information was collected
about the occurrence, frequency and number of mammography, MRI,
and ovarian ultrasound examinations undergone during the previous
3 years. The same questions were also asked about mammography and
ovarian ultrasound at the 1- and 2-year follow-ups but the question about
MRI was asked only at the 5-year follow-up, since the medical guidelines only
recommended this type of investigation for the ﬁrst time in 2004 (Eisinger
et al15,16). The occurrence of prophylactic surgery was cross-checked with the
medical records. Details about prophylactic surgery (RRM and RRSO) were
collected before disclosure of results and then again at the 1-, 2- and 5-year
follow-ups. Baseline preventive behaviours had been asked in the pre-disclosure
questionnaire.
Perception of personal risk of cancer. Perception of the personal risk of
developing breast cancer was measured on a six-point Likert scale before
disclosure and at follow-up by asking the same question: ‘Do you think your
risk of developing breast cancer is: ‘very high’, ‘high’, ‘moderate’, ‘low’, ‘very low’
and ‘don’t know’. The same questions were asked about respondents’ percep-
tion of their risk of developing ovarian cancer and about their perception of the
risk of developing cancer of other kinds.
Sociodemographic, psychological and medical characteristics
Sociodemographic variables such as age, number of children, level of education,
occupation, previous preventive behaviour and psychological variables were
collected at baseline for all the women included and updated during follow-up.
The medical characteristics included the number of ﬁrst- and second-degree
relatives affected with breast/ovarian cancer at inclusion, and the deleterious
BRCA1/2 mutation involved.
Statistical analysis
Chi-square tests, t-tests and ANOVAwere used to make univariate comparisons
on categorical and continuous variables. McNemar’s w2 tests were used to
compare respondents’ cancer risk perceptions at different times. The level of
statistical signiﬁcance (a-error) was taken to be Pr0.05.
Data analysis was conducted in three stages.
  To check how representative the ﬁnal sample was after 5 years, the
respondents’ and non-respondents’ baseline sociodemographic, psycho-
social and medical characteristics were compared.
  The preventive strategies used by carriers/non-carriers were recorded at the
5-year follow-up. They are presented in a decision tree and the two groups
were then compared after stratifying the results by age group. The sequences
of preventive options chosen by BRCA1/2 carriers were analysed at the
5-year follow-up.
  High/very high breast, ovarian and other cancer risk perceptions docu-
mented at various times were studied, depending on the preventive
strategies chosen (or not) by carriers/non-carriers. High- and very high-
risk perception levels were grouped together and denoted ‘high’ perceptions.
  The Statistical Package for Social Science (SPSS/PC released 17.0) was used
to perform all the statistical analyses (SPSS Inc., Chicago, IL, USA).
RESULTS
Respondents vs non-respondents
Among the 345 women who completed the ﬁrst questionnaire before
test result disclosure and who should have reached the 5 years follow-
up endpoint, 14 were excluded because they had developed breast
cancer (N¼12) or ovarian cancer (N¼2) by the ﬁfth year of follow-up;
all 14 were BRCA1/2 mutation carriers. Among the unaffected women
at 5 years (N¼331), 246 (74%) completed all ﬁve questionnaires and
were included in this analysis.
Respondents and non-respondents did not differ signiﬁcantly in
their baseline sociodemographic, psychological or medical character-
istics. However, respondents had reported doing breast self-examina-
tion signiﬁcantly more frequently than non-respondents (Pr0.05) in
the baseline questionnaire.
Sample characteristics
Among these 246 women, 41% (N¼101) were carriers of a familial
BRCA1/2 mutation, whereas 59% (N¼145) were non-carriers.
The mean age of the BRCA1/2 carriers at the time of disclosure was
37.2 years (SD¼10.2), which differed signiﬁcantly from that of the
non-carriers (41.7±11.8) (±SD) (P¼0.002). The level of education,
marital status and number of children did not differ signiﬁcantly
between BRCA1/2 mutation carriers and non-carriers. Medical char-
acteristics, such as the number of ﬁrst-degree relatives affected were
also similar between carriers and non-carriers. Respondents’ charac-
teristics are given in Table 1. The 246 respondents belonged to 166
different families: 68.1% (N¼113) of these families were represented
in the sample by a single woman, whereas the remaining, 31.9%
(N¼53) were represented by several members, numbering 2.5 on
average (median 2; range 2–6). Among the 18 centres who reported
carriers, 3 had reported 56.5% of the cases analysed (N¼57) and 15
had reported the remaining 44.5% (N¼44). The average number of
carriers by centre was 5.6 (range 1–31).
Risk perception 5 years after BRCA1/2 test result
C Julian-Reynier et al
501
European Journal of Human GeneticsPreventive strategies in mutation carriers/non-carriers after
disclosure of the BRCA1/2 test results
Carriers (N¼101). A decision tree was drawn up describing the
seven strategies documented at the 5-year follow-up, including
prophylactic surgery and breast imaging (Figure 1). As transvaginal
ultrasound is not thought to be an effective17 means of improving
ovarian cancer prognosis and is not ofﬁcially recommended in
France,15,16 it was not included in these decision trees but noted
separately. Four strategies accounted for 88% of the preventive options
chosen by the carriers at the end of the 5-year follow-up: 50% had
opted for breast surveillance alone, based on either MRI and other
imaging methods in 31% of cases (N¼31; strategy S5), or based on
mammography alone in 19% (N¼19; S6); 38% had opted for RRSO
and breast surveillance based on MRI and/or other imaging
methods in 28% of cases (N¼28; S3) or mammography alone in
10% (N¼10; S4). The other three strategies documented were
RRM and RRSO (5%) (N¼5; S1), RRM alone (N¼2; 2%; S2), and
neither RRM/RRSO nor surveillance (N¼6; 6%; S7). One 45-year-old
woman who had opted for S2 planned to undergo RRSO 5 weeks after
completing the ﬁnal questionnaire; the other one was 48 years old and
had no family history of ovarian cancer. In the S7 group, two women
were under 30 years of age; the others were aged between 31 and 39
years. These strategies were stratiﬁed by age, above and below 40 years
of age, as shown in Figures 2a and b.
Among the carriers. RRM was undergone by 7%, and this option
was not correlated with the women’s age. RRSO was undergone by
43% of the carriers, and this option was chosen signiﬁcantly more
frequently with age (Po0.001): the rate of uptake increased from 18%
in the 30–39-year olds to 65% in those Z40 years of age. During the
last 3 years, the women underwent 2.8 mammograms on average and
1.7 MRI on average (Table 2). MRI was undergone by 63% (in 59/94
cases without RRM), and no correlations were observed with age
in this respect. A high rate of ovarian ultrasound screening was
still observed during the last 3 years among those who underwent
no RRSO. The results obtained on each age group are presented in
Table 2.
Non-carriers (N¼145). No RRM was performed on non-carriers
after disclosure of the results, but three salpingo-oophorectomies were
undergone by non-carriers for other medical reasons (ﬁbroma or
cystic ovaries) (Table 2). In all, 53% of the women aged between
30 and 39 years (20% of the o30 age group) reported at the ﬁnal
follow-up that they had continued to undergo annual or 2-yearly
Table 1 Baseline medical and sociodemographic characteristics of
study population (N¼246)
Carriers (N¼101) Non-carriers (N¼145)
n % n % P*
Having ﬁrst-degree relatives with breast cancer (n¼218)
02 9 3 0 . 9 3 5 2 8 . 2 0 . 2 1 2
15 0 5 3 . 2 5 7 4 6 . 0
Z21 5 1 6 . 0 3 2 2 5 . 8
Having ﬁrst-degree relatives with ovarian cancer (n¼220)
05 8 6 1 . 1 7 3 5 8 . 4 0 . 6 9 1
Z13 7 3 9 . 0 5 2 4 1 . 6
Married (n¼243)
Yes 58 58.6 97 67.4 0.162
No 41 41.4 47 32.6
Educational background (n¼242)
4High school 59 58.4 74 52.5 0.360
rHigh school 42 41.6 67 47.5
Children (n¼220)
Yes 67 81.7 110 79.7 0.718
No 15 18.3 28 20.3
*w2 test.
Proportions do not always add up to 100% because of rounding.
BRCA1/2 carriers
(n=101)
No mastectomy
(94)
No RRSO
(n=56)
RRSO
(n=38)
No MRI (n=25)
MRI (n=31)
Mastectomy
(n=7)
RRSO
(n=5)
No RRSO
(n=2)
MRI (n=28) 
No MRI
(n=10)
Mammo (n=10)
Mammo (n=31)
Mammo (n=19)
No Mammo (n=6)
p=0.07
p=0.93
p=0.71
p=0.29
p=0.40
p=0.60
p=0.74
p=0.26
p=0.55
p=0.45
Mammo (n=28)
p=0.76
p=0.24
S1=0.05
S2=0.02
S3=0.28
S4=0.10
S5=0.31
S6=0.19
S7=0.06
Figure 1 Preventive management strategies observed in BRCA1/2 mutation carriers (N¼101) 5 years after test result disclosure.
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European Journal of Human Geneticsmammography during the previous 3 years; only 7 (4.8%) had
undergone MRI; 43.2% stated that they had undergone an ovarian
ultrasound examination during the last 3 years.
High perceptions of breast/ovarian cancer risks vs preventive strategies
and mutation carrier/non-carrier status. Disclosure of the BRCA1/2
status signiﬁcantly affected the carriers and non-carriers’ high percep-
tions of breast/ovarian cancer risks. Among the carriers, it signiﬁcantly
increased the proportion of carriers with high/very high breast cancer
risk perceptions (from 63% before disclosure to 81% 6 months after
disclosure, McNemar’s w2, P¼0.016) and some carriers’ high ovarian
cancer risk perceptions (from 42% before disclosure to 62% 6 months
after disclosure, McNemar’s w2 P¼0.007); whereas it decreased high
breast cancer risk perceptions (N¼145) (Figure 3; Po0.001) and high
ovarian cancer risk perceptions (Figure 4; Po0.001) in non-carriers.
High perception of other cancer risks was relatively infrequent and not
affected by disclosure (12.1 and 9.5% before disclosure and 6 months
after disclosure, respectively, McNemar’s w2 P¼0.248 and 11.2, 7.9 and
15.5% after 1, 2 and 5 years, respectively).
All those who eventually opted for RRM by the ﬁfth year of follow-
up (strategies S1 and S2 in Figure 1; N¼7) had high breast cancer risk
perceptions before disclosure; these high perceptions decreased with
time after disclosure and after undergoing RRM (Figure 3). High breast
cancer risk perceptions increased steadily with time among all the other
carriers, regardless of whether or not they opted for RRSO (strategies S3
and S4 in Figure 1; N¼38) or not (strategies S5–S7, Figure 1; N¼56).
High ovarian cancer risk perceptions with time showed the same
pattern as with breast cancer. Among carriers who did not opt for
RRM, those who opted for RRSO (strategies S3–S4 in Figure 1) had
higher ovarian cancer risk perceptions before disclosure than those who
did not (Figure 4; P¼0.014). Between 6 and 60 months after disclosure
of the results, these high perceptions decreased signiﬁcantly after RRSO
(McNemar; P¼0.002), whereas a signiﬁcant increase (McNemar;
P¼0.049) occurred among those who did not opt for surgery.
p=0.05
p=0.95
p=1.00
p=0.00
p=0.12
p=0.88
p=0.80
p=0.20
p=0.59
p=0.41
p=0.60
p=0.40
< 40 years
(n=44)
No mastectomy
(n=42)
No RRSO
(n=37)
RRSO
(n=5)
No MRI (n=15)
MRI (n=22)
Mastectomy
(n=2)
No RRSO
(n=0)
MRI (n=4)
No MRI (n=1) Mammo (n=1)
Mammo (n=22)
Mammo (n=9)
No Mammo (n=6)
Mammo (n=4)
RRSO
(n=2) S1=0.05
S2=0.00
S3=0.09
S4=0.02
S5=0.50
S6=0.21
S7=0.14
No MRI (n=9)
p=0.09
p=0.91
p=0.60
p=0.40
p=0.64
p=0.37
p=0.73
p=0.27
p=0.47
p=0.53
p=1.00
p=0.00
Mastectomy
(n=5)
RRSO
(n=3)
No RRSO
(n=2)
No mastectomy
(n=52)
No RRSO
(n=19)
RRSO
(n=33)
No MRI (n=10)
MRI (n=9)
MRI (n=24) 
Mammo (n=9)
Mammo (n=9)
Mammo (n=10)
No Mammo (n=0)
Mammo (n=24) ≥ 40 years
 (n=57)
S1=0.05
S2=0.04
S3=0.42
S4=0.16
S5=0.16
S6=0.18
S7=0.00
Figure 2 (a) Preventive management strategies observed in BRCA1/2 mutation carriers o40 years (N¼44) 5 years after test result disclosure. (b) Preventive
management strategies observed in BRCA1/2 mutation carriers Z40 years (N¼57) 5 years after test result disclosure.
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This is the ﬁrst time the preventive strategies used by a French national
cohort of unaffected female BRCA1/2 carriers and non-carriers have
been documented for 5 years after routine genetic test result
disclosure. The preventive strategies reported by respondents 5 years
after disclosure show that in France, regular MRI surveillance (along
with other breast imaging methods) is the most frequently preferred
strategy among unaffected female BRCA1/2 carriers under 40 years of
age, whereas RRSO tends to be combined with regular MRI breast
imaging among older women (Figures 2a and b). When the decision
to undergo RRM has been made, RRSO is generally undergone
as well (Figure 1). Transvaginal ultrasound investigations were
undergone regularly by carriers without RRSO, and non-carriers
appeared to favour opting for screening despite their low cancer risk
(Table 2). In France, this screening is possible when prescribed by a
medical practitioner. High breast/ovarian cancer risk perceptions were
signiﬁcantly affected in both the short- and long-term among carriers
and non-carriers alike. In the long run, high breast cancer risk
perceptions increased steadily with time among those without RRM
(and decreased among the small sample with RRM), and a similar
pattern was observed in the case of ovarian cancer risk perception and
RRSO. RRSO had no effect on breast cancer risk perceptions.
It was reported some time ago that there is little enthusiasm in
France for RRM, either among health professionals or women
attending cancer genetic clinics.18,19 The present results conﬁrm the
reluctance previously observed about these issues, although the rate of
uptake of RRSO in France is comparable to that of other countries in
Table 2 Preventive strategies adopted by BRCA1/2 carriers and non-carriers (all unaffected) 5 years after test result disclosure (N¼246)
Carriers (N¼101) Non-carriers (N¼145)
Age category Age category
Total o30 n¼63 0 – 3 9 n¼38 40–49 n¼36 Z50 n¼21 Total o30 n¼10 30–39 n¼32 40–49 n¼44 Z50 n¼59
Preventive strategies n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Bilateral prophylactic mastectomy
after test result delivery
7 (6.9) 0 2 (5.3) 4 (11.1) 1 (4.8) 0 0 0 0 0
Bilateral prophylactic oophorectomy 43 (42.6) 0 7 (18.4) 20 (55.6) 16 (76.2) 17 (11.7) 0 0 3 (6.8) 14 (23.7)
Before test result delivery 2 1 1 0 14 1 13
After test result delivery 41 6 19 16 3 2 1
m( S D ) a m( S D ) a m( S D ) a m( S D ) a m( S D ) a m( S D ) a m (SD) m (SD) m (SD) m (SD)
Mammograms during the previous 3 yearsb 2.8 (1.4) 1.8 (2.3) 2.6 (1.4) 3.1 (1.4) 3.2 (1.1) 1.7 (1.2) 0.5 (1.3) 0.9 (1.0) 1.7 (1.1) 2.2 (1.1)
MRI during the previous 3 yearsb 1.7 (1.7) 1.5 (2.1) 1.5 (1.5) 2.2 (2.0) 1.2 (1.4) 0.1 (0.4) 0.2 (0.7) 0.0 (0.2) 0.1 (0.5) 0.1 (0.3)
Ovarian ultrasoundc
Transvaginal US 1.7 (1.7) 0.5 (1.2) 1.4 (1.7) 2.3 (1.6) 2.6 (2.3) 0.7 (1.4) 0.6 (1.9) 1.0 (1.6) 0.5 (1.3) 0.6 (1.1)
Abdominal US 0.6 (1.2) 0.7 (1.2) 0.8 (1.5) 0.2 (0.8) 0 (0) 0.4 (1.2) 0.1 (0.3) 0.2 (0.8) 0.8 (1.8) 0.3 (0.8)
aMean number of investigations undergone during the last 3 years (means and SD).
bApart from RRM.
cApart from RRSO.
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Before
test
6 months
carriers RRM* (n=7) carriers RRSO (n=38)
carriers no RRS (n=56) non carriers (n=145)
60 months 24 months 12 months
Figure 3 High perceptions of breast cancer risks before/after BRCA1/2 test
result disclosure, depending on prophylactic surgery undergone during
follow-up (N¼246). *RRM+RRSO (n¼5) or RRM alone (n¼2).
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Before test
carriers RRM* (n=7) carriers RRSO (n=38)
carriers no RRS (n=56) non carriers (n=145)
60 months 24 months 12 months 6 months
Figure 4 High perceptions of ovarian cancer risks before/after BRCA1/2 test
result disclosure, depending on prophylactic surgery undergone at follow-up
(N¼246). *RRM+RRSO (n¼5) or RRM alone (n¼2).
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European Journal of Human Geneticsthe relevant age groups. Health professionals in France seem to expect
MRI to be a highly effective means of detecting early forms of breast
cancer, resulting in a good prognosis, whereas those in other countries
prefer the highly effective surgical strategies available. It would be
interesting to know the survival rates associated with each combina-
tion of preventive strategies, which would help to give women all the
information required for their decision making to be autonomous and
well informed.
It is worth discussing the increase observed here in the high breast/
ovarian cancer risk perceptions of those who did not undergo risk
reducing surgery, as well as the fact that RRSO did not decrease high
breast cancer risk perceptions although this intervention is known to
signiﬁcantly decrease the risk of breast cancer.20 Finch et al21 retro-
spectively assessed the impact of genetic counselling and RRSO on
breast and ovarian cancer risk knowledge and concluded that most
women accurately perceived their breast cancer risks. Our results
mean either that the information was not delivered by health-care
professionals or that RRSO had no impact on a priori lay beliefs about
breast cancer risks. Cancer risk perception is a complex and subjective
issue, because risk perception seems to have nothing to do with ‘risk
knowledge’. Risk perception is known to determine behaviour, whereas
people’s ‘risk knowledge’ is not predictive of their health-related
behaviour.22 Risk perception may decrease when the main target
organ of cancer has been removed surgically, whereas the situation
is not the same when another organ is taken out, and the preventive
action obtained through the suppression of hormonal effect. Previous
studies have shown that women’s psychological distress decreases after
undergoing prophylactic mastectomy,23 and that their fear of devel-
oping cancer also decreases,6 which is similar to what occurs with
high-risk perception or affective risk perception.24 However, other
investigators have reported that the levels of distress are still high after
these interventions, especially RRSO,25 possibly because these women’s
perception of the remaining risk of breast cancer has not changed
signiﬁcantly.
Our study had several limitations. First, respondents always differ
from non-respondents, even if they have the same baseline character-
istics. Only baseline breast self-examination practices differed here
between respondents and non-respondents; therefore, we must
remember that our results may not be completely representative of
the whole cohort or of the whole French population of BRCA1/2
carriers, although we beneﬁted from the advantages of multicentre,
nationwide recruitment. Second, the same bias occurred as in previous
studies, as following the same group of people with questionnaires
may affect their spontaneous decisions during follow-up and hence
the methods of surveillance and prevention they choose. We also have
to take the time factor into account, since preventive recommenda-
tions evolve with time and while the people in this study were being
tested, new preventive recommendations were issued in 2004, espe-
cially as regards prophylactic surgery, which was more strongly
recommended16 than previously.15
In conclusion, women’s cancer risk perceptions 5 years after
disclosure of their BRCA1/2 status depend on decisions about
preventive interventions more than simply on the outcomes of
mutation tests. Women need to know more these days about the
probability of survival associated with all the strategies available, and
in particular whether opting for RRSO and breast MRI surveillance is
likely to be as effective as undergoing both RRM and RRSO in terms
of survival.
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